Aspirin decreases fibrinolytic potential during venous occlusion, but not during acute physical activity

Thrombosis Research
|April 15, 1987
PubMed

It has previously been observed that aspirin diminishes the increase in blood fibrinolytic activity during arm venous occlusion. We studied the duration of this inhibitory effect on fibrinolytic response during 20 minutes arm venous occlusion and its effect on fibrinolytic response during acute physical activity (standardized stress testing on treadmill) in 10 healthy male volunteers. Fibrinolytic activity was measured with euglobulin clot lysis time and fibrin plates before and after both stimuli, and t-PA release estimated as the difference between post- and prestimulation values (fibrinolytic potential: FP). Venous occlusions were performed before aspirin ingestion and then on the first, second, third, and fourth to eighth day after aspirin. Stress testing was carried out on two successive days before and after aspirin ingestion. Aspirin did not affect basal fibrinolytic activity, but significantly decreased FP during occlusion. This effect was sustained for the whole period of observation. To the contrary, aspirin did not influence FP during acute physical activity. The different effect of aspirin on fibrinolytic response during venous occlusion and physical activity suggested that different mechanisms were involved in t-PA release during both stimuli.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Vascular Spasm01:16

Vascular Spasm

The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last for...